Compare Stocks: BCDA, RNTX, INKT, and XLO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCDA BioCardia	$1.04 +2.0%	$1.02	$0.75 ▼ $1.80	$15.74M	0.62	360,409 shs	52,537 shs
INKT MiNK Therapeutics	$12.44 -2.3%	$11.55	$8.48 ▼ $16.93	$63.48M	0.47	18,725 shs	48,867 shs
RNTX Rein Therapeutics	$0.80 -6.0%	$0.79	$0.69 ▼ $2.18	$69.07M	1.35	383,509 shs	477,517 shs
XLO Xilio Therapeutics	$9.01 +1.1%	$9.08	$6.47 ▼ $12.58	$59.29M	-0.15	9,366 shs	7,400 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCDA BioCardia	0.00%	-0.95%	-4.59%	-13.33%	-21.80%
INKT MiNK Therapeutics	0.00%	+2.13%	+10.77%	+6.60%	-15.14%
RNTX Rein Therapeutics	0.00%	+6.99%	-5.09%	-19.24%	-32.14%
XLO Xilio Therapeutics	0.00%	-0.33%	-0.11%	-1.53%	-22.70%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCDA BioCardia	$1.04 +2.0%	$1.02	$0.75 ▼ $1.80	$15.74M	0.62	360,409 shs	52,537 shs
INKT MiNK Therapeutics	$12.44 -2.3%	$11.55	$8.48 ▼ $16.93	$63.48M	0.47	18,725 shs	48,867 shs
RNTX Rein Therapeutics	$0.80 -6.0%	$0.79	$0.69 ▼ $2.18	$69.07M	1.35	383,509 shs	477,517 shs
XLO Xilio Therapeutics	$9.01 +1.1%	$9.08	$6.47 ▼ $12.58	$59.29M	-0.15	9,366 shs	7,400 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCDA BioCardia	0.00%	-0.95%	-4.59%	-13.33%	-21.80%
INKT MiNK Therapeutics	0.00%	+2.13%	+10.77%	+6.60%	-15.14%
RNTX Rein Therapeutics	0.00%	+6.99%	-5.09%	-19.24%	-32.14%
XLO Xilio Therapeutics	0.00%	-0.33%	-0.11%	-1.53%	-22.70%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCDA BioCardia	2.00	Hold	$25.00	2,303.85% Upside
INKT MiNK Therapeutics	2.00	Hold	$35.00	181.35% Upside
RNTX Rein Therapeutics	2.25	Hold	$6.00	649.34% Upside
XLO Xilio Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest BCDA, RNTX, INKT, and XLO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/24/2026	BCDA BioCardia	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/21/2026	RNTX Rein Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	RNTX Rein Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2026	INKT MiNK Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2026	BCDA BioCardia	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/6/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/3/2026	RNTX Rein Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/20/2026	RNTX Rein Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.00
7/17/2026	BCDA BioCardia	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCDA BioCardia	$60K	262.43	N/A	N/A	$0.08 per share	13.00
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	($3.03) per share	N/A
RNTX Rein Therapeutics	N/A	N/A	$0.06 per share	14.00	($1.07) per share	N/A
XLO Xilio Therapeutics	$43.77M	1.35	N/A	N/A	$7.31 per share	1.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCDA BioCardia	-$8.23M	-$0.64	N/A	N/A	N/A	N/A	-569.36%	-183.15%	11/11/2026 (Estimated)
INKT MiNK Therapeutics	-$12.49M	-$2.40	N/A	N/A	N/A	N/A	N/A	-92.37%	11/12/2026 (Estimated)
RNTX Rein Therapeutics	-$49.87M	-$1.72	N/A	N/A	N/A	N/A	N/A	-63.69%	N/A
XLO Xilio Therapeutics	-$35.04M	-$1.64	N/A	N/A	N/A	-34.06%	-71.99%	-20.43%	11/5/2026 (Estimated)

Latest BCDA, RNTX, INKT, and XLO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	RNTX Rein Therapeutics	-$0.27	-$0.10	+$0.17	-$0.10	N/A	N/A
8/13/2026	Q2 2026	INKT MiNK Therapeutics	-$0.60	-$0.62	-$0.02	-$0.62	N/A	N/A
8/13/2026	Q2 2026	XLO Xilio Therapeutics	-$0.59	-$0.33	+$0.26	-$0.33	$12.72 million	$18.69 million
8/12/2026	Q2 2026	BCDA BioCardia	-$0.18	-$0.13	+$0.05	-$0.13	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCDA BioCardia	N/A	N/A	N/A	N/A	N/A
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCDA BioCardia	N/A	2.09	2.09
INKT MiNK Therapeutics	N/A	1.23	1.23
RNTX Rein Therapeutics	N/A	4.27	4.27
XLO Xilio Therapeutics	N/A	4.25	4.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCDA BioCardia	20.57%
INKT MiNK Therapeutics	2.87%
RNTX Rein Therapeutics	90.89%
XLO Xilio Therapeutics	54.29%

Insider Ownership

Company	Insider Ownership
BCDA BioCardia	17.40%
INKT MiNK Therapeutics	20.40%
RNTX Rein Therapeutics	1.50%
XLO Xilio Therapeutics	7.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCDA BioCardia	21	15.14 million	12.51 million	Optionable
INKT MiNK Therapeutics	15	5.10 million	4.06 million	No Data
RNTX Rein Therapeutics	10	86.27 million	84.97 million	N/A
XLO Xilio Therapeutics	76	6.58 million	6.09 million	Not Optionable

BCDA, RNTX, INKT, and XLO Headlines

Recent News About These Companies

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2 at 4:30 PM | globenewswire.com

Xilio Names Yariv Houvras Chief Medical Officer

September 28, 2026 | rttnews.com

Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer

September 28, 2026 | markets.businessinsider.com

Xilio Therapeutics Appoints Yariv J. Houvras, M.D.

September 28, 2026 | globenewswire.com

Xilio Therapeutics Grants Inducement Stock Options to New Employees Under 2022 Plan

September 2, 2026 | quiverquant.comQ

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 2, 2026 | globenewswire.com

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

August 12, 2026 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 6, 2026 | markets.businessinsider.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 6, 2026 | globenewswire.com

Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

June 29, 2026 | finanznachrichten.de

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

June 29, 2026 | globenewswire.com

Xilio Therapeutics Inc

June 2, 2026 | edition.cnn.com

Cancer Stocks That Are Advancing the Future of Oncology Care

May 18, 2026 | zacks.com

Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates

May 12, 2026 | zacks.com

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

May 12, 2026 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 7, 2026 | globenewswire.com

Xilio Therapeutics (XLO) price target decreased by 28.57% to 20.40

April 28, 2026 | msn.com

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

April 17, 2026 | globenewswire.com

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors

April 16, 2026 | markets.businessinsider.com

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.

April 16, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCDA, RNTX, INKT, and XLO Company Descriptions

BioCardia NASDAQ:BCDA

$1.04 +0.02 (+1.96%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.04 +0.00 (+0.48%)

As of 10/2/2026 04:10 PM Eastern

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

MiNK Therapeutics NASDAQ:INKT

$12.44 -0.29 (-2.28%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$12.50 +0.06 (+0.48%)

As of 10/2/2026 07:33 PM Eastern

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Rein Therapeutics NASDAQ:RNTX

$0.80 -0.05 (-6.03%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.79 -0.01 (-1.46%)

As of 10/2/2026 07:30 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Xilio Therapeutics NASDAQ:XLO

$9.01 +0.10 (+1.12%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$8.98 -0.03 (-0.28%)

As of 10/2/2026 07:30 PM Eastern

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCDA, RNTX, INKT, and XLO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCDA, RNTX, INKT, and XLO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCDA, RNTX, INKT, and XLO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCDA, RNTX, INKT, and XLO Company Descriptions

BioCardia NASDAQ:BCDA

MiNK Therapeutics NASDAQ:INKT

Rein Therapeutics NASDAQ:RNTX

Xilio Therapeutics NASDAQ:XLO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCDA, RNTX, INKT, and XLO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCDA, RNTX, INKT, and XLO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCDA, RNTX, INKT, and XLO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCDA, RNTX, INKT, and XLO Company Descriptions

BioCardia NASDAQ:BCDA

MiNK Therapeutics NASDAQ:INKT

Rein Therapeutics NASDAQ:RNTX

Xilio Therapeutics NASDAQ:XLO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools